TrialJournal of translational medicine2016

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.

Raya Leibowitz-Amit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.